200 related articles for article (PubMed ID: 24700565)
21. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade.
Giganti F; De Cobelli F; Canevari C; Orsenigo E; Gallivanone F; Esposito A; Castiglioni I; Ambrosi A; Albarello L; Mazza E; Gianolli L; Staudacher C; Del Maschio A
J Magn Reson Imaging; 2014 Nov; 40(5):1147-57. PubMed ID: 24214734
[TBL] [Abstract][Full Text] [Related]
22. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
[TBL] [Abstract][Full Text] [Related]
23. PET/CT in brachytherapy early response evaluation of pancreatic ductal adenocarcinoma xenografts: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging.
Liu Y; Liu M; Liu X; Zhou Y
Abdom Radiol (NY); 2019 Mar; 44(3):950-957. PubMed ID: 30315322
[TBL] [Abstract][Full Text] [Related]
24. Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT.
Wulfert S; Kratochwil C; Choyke PL; Afshar-Oromieh A; Mier W; Kauczor HU; Schenk JP; Haberkorn U; Giesel FL
Mol Imaging Biol; 2014 Aug; 16(4):586-94. PubMed ID: 24526358
[TBL] [Abstract][Full Text] [Related]
25. Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.
Toledano-Massiah S; Luciani A; Itti E; Zerbib P; Vignaud A; Belhadj K; Baranes L; Haioun C; Lin C; Rahmouni A
Radiographics; 2015; 35(3):747-64. PubMed ID: 25815803
[TBL] [Abstract][Full Text] [Related]
26. Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.
De Paepe KN; Van Keerberghen CA; Agazzi GM; De Keyzer F; Gheysens O; Bechter O; Wolter P; Dierickx D; Janssens A; Verhoef G; Oyen R; Koole M; Vandecaveye V
Radiol Imaging Cancer; 2021 Mar; 3(2):e200061. PubMed ID: 33817648
[TBL] [Abstract][Full Text] [Related]
27. To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma).
Gupta N; Singh N
Nucl Med Commun; 2020 Apr; 41(4):395-404. PubMed ID: 32073552
[TBL] [Abstract][Full Text] [Related]
28. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma.
Lin C; Luciani A; Itti E; El-Gnaoui T; Vignaud A; Beaussart P; Lin SJ; Belhadj K; Brugières P; Evangelista E; Haioun C; Meignan M; Rahmouni A
Eur Radiol; 2010 Aug; 20(8):2027-38. PubMed ID: 20309558
[TBL] [Abstract][Full Text] [Related]
29. Correlation between glycolytic activity on [18F]-FDG-PET and cell density on diffusion-weighted MRI in lymphoma at staging.
Giraudo C; Karanikas G; Weber M; Raderer M; Jaeger U; Simonitsch-Klupp I; Mayerhoefer ME
J Magn Reson Imaging; 2018 May; 47(5):1217-1226. PubMed ID: 29086453
[TBL] [Abstract][Full Text] [Related]
30. Diffusion-weighted MRI and PET/CT reproducibility in epithelial ovarian cancers during neoadjuvant chemotherapy.
Crombé A; Gauquelin L; Nougaret S; Chicart M; Pulido M; Floquet A; Guyon F; Croce S; Kind M; Cazeau AL
Diagn Interv Imaging; 2021 Oct; 102(10):629-639. PubMed ID: 34112625
[TBL] [Abstract][Full Text] [Related]
31. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization.
Barabasch A; Kraemer NA; Ciritsis A; Hansen NL; Lierfeld M; Heinzel A; Trautwein C; Neumann U; Kuhl CK
Invest Radiol; 2015 Jun; 50(6):409-15. PubMed ID: 25763526
[TBL] [Abstract][Full Text] [Related]
33. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
[TBL] [Abstract][Full Text] [Related]
34. Comparison of different MRI sequences in lesion detection and early response evaluation of diffuse large B-cell lymphoma--a whole-body MRI and diffusion-weighted imaging study.
Wu X; Nerisho S; Dastidar P; Ryymin P; Järvenpää R; Pertovaara H; Eskola H; Kellokumpu-Lehtinen PL
NMR Biomed; 2013 Sep; 26(9):1186-94. PubMed ID: 23483722
[TBL] [Abstract][Full Text] [Related]
35. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.
Stéphane V; Samuel B; Vincent D; Joelle G; Remy P; Francois GG; Jean-Pierre T
Eur J Radiol; 2013 Nov; 82(11):2011-7. PubMed ID: 23932096
[TBL] [Abstract][Full Text] [Related]
36. DW MRI at 3.0 T versus FDG PET/CT for detection of malignant pulmonary tumors.
Zhang J; Cui LB; Tang X; Ren XL; Shi JR; Yang HN; Zhang Y; Li ZK; Wu CG; Jian W; Zhao F; Ti XY; Yin H
Int J Cancer; 2014 Feb; 134(3):606-11. PubMed ID: 23893610
[TBL] [Abstract][Full Text] [Related]
37. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
38. (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.
Mylam KJ; Kostakoglu L; Hutchings M; Coleman M; Lamonica D; Czuczman MS; Diehl LF; Nielsen AL; Jensen P; Loft A; Hendel HW; Iyer V; Leppä S; Jyrkkiö S; Holte H; Eriksson M; Gillstrøm D; Hansen PB; Seppänen M; Hjorthaug K; Brown Pde N; Pedersen LM
Leuk Lymphoma; 2015 Jul; 56(7):2005-12. PubMed ID: 25330442
[TBL] [Abstract][Full Text] [Related]
39. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
[TBL] [Abstract][Full Text] [Related]
40. Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study.
Lin C; Itti E; Luciani A; Zegai B; Lin SJ; Kuhnowski F; Pigneur F; Gaillard I; Paone G; Meignan M; Haioun C; Rahmouni A
Invest Radiol; 2011 May; 46(5):341-9. PubMed ID: 21263330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
